Obesity and Breast Cancer: An Ever Growing Problem Presented By: Dr. Jaixin Niu Dr. Adam Kerievsky Brenda Keith RN MSN OCN Amy Malensek RN OCN CBCN Sara

Obesity and Breast Cancer: An Ever Growing Problem

Presented By:Dr. Jaixin Niu

Dr. Adam KerievskyBrenda Keith RN MSN OCN

Amy Malensek RN OCN CBCNSara Kiser MS ND

Obesity and Breast Cancer: A Medical Oncologist’s Perspective

Presented By:Dr. Jiaxin Niu

© 2015 Rising Tide

Obesity and Breast CancerObesity and Breast Cancer

Obesity: Body Mass Index (BMI) of 30 or higher

Obesity itself was recognized as a disease by the American Medical Association in 2013

© 2015 Rising Tide

Prevalence of ObesityPrevalence of Obesity

USA: 32% of men, 34% women

Western Europe: 21% in both Sexes

Southeast Asia: 8% men, 5% WomenLancet, 2014

© 2015 Rising Tide

© 2015 Rising Tide

Obesity Predicted to Top 60% in 13 States by 2030

Source: Trust for America's Health and the Robert Wood Johnson Foundation

2013 POLL:

RISKS OF OBESITY

7% of People surveyed mentioned cancer !!!

© 2015 Rising Tide

© 2015 Rising Tide

Obesity Increases Cancer Risk

Obesity may account for roughly 10% of colorectal cancers, and 25-40% of kidney, esophageal and endometrial cancers

As many as 80, 000 cancer diagnoses each year are attributed to Obesity.

Obesity will overtake tobacco as the leading preventable cause of cancer.

OBESITY AND BREAST CANCER

1. Obesity is a risk factor for breast cancer

2. Diagnostic and therapeutic challenges

3. Obesity is a poor prognostic factor

© 2015 Rising Tide

Breast Cancer

Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014

Approximately 63, 000 new cases of carcinoma in situ (CIS) will be diagnosed

© 2015 Rising Tide

© 2015 Rising Tide

Your Breast Cancer Risk

• 1 in 8 women (12.4%) born in the US will develop breast cancer at some time during their lifetime

Howlader N, et al SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), 2012.

• ~ 3 million breast cancer survivors at this time

© 2015 Rising Tide

Nurses’ Health Study: Obesity Increases Breast Cancer Risk

87143 female nurses aged 30-55 years followed up to 26 years (1976-2002), 4393 developed breast cancer >10 Kg since age 18, 20% postmenopausal non-hormone users

Eliassen et al. JAMA 2006; 296: 193

>25 Kg since age 18, 100% postmenopausal non-hormone users

© 2015 Rising Tide

87143 female nurses aged 30-55 years followed up to 26 years (1976-2002), 4393 developed breast cancer


15% of breast cancer is attributable to weight gain of 2.0 kg or more since age 18 years

Obesity + Hormonal replacement, they account for 1/3 breast cancer cases


© 2015 Rising Tide


87143 female nurses aged 30-55 years followed up to 26 years (1976-2002), 4393 developed breast cancer


Non-hormone users, sustained weight loss of at least 10 Kg after menopause resulted in a 57% reduction in breast cancer risk

© 2015 Rising Tide

Obesity Increases Breast Cancer Risk

Sinicrope, FA, Dannenberg AJ. JCO 2010

Obesity: Advanced Stage

Upon Diagnosis

a. Larger Tumorb. Higher Gradec. HR-Negative Tumord. More Positive LNs

Breast Cancer Res Treat. 2008 Sep;111(2):329-42. Breast Cancer Res Treat. 2010 Aug;122(3):823-33.J Clin Oncol. 2011 Jan 1;29(1):25-31.

© 2015 Rising Tide

Obesity: Therapeutic Challenges

Wound healingLymphedemaRadiation planning

Breast Cancer Res Treat. 2008 Sep;111(2):329-42. Breast Cancer Res Treat. 2010 Aug;122(3):823-33.J Clin Oncol. 2011 Jan 1;29(1):25-31.

Delivery of systemic therapy

© 2015 Rising Tide


Timing of Chemotherapy

Biagi JJ, et al. J Clin Oncol 29: 111s, 2011Colleoni M, et al. J Clin Oncol 18: 584-590, 2000

Meta-analysis of 15,327 patients : initiation of Adjuvant chemotherapy

Each 4-week delay: 8% in recurrence

HR- patients: initiation of Adjuvant chemotherapy

< 20 days vs 21-86 days: 60% vs 34% 10-year DFS

© 2015 Rising Tide


Dosing of Chemotherapy

Biagi JJ, et al. J Clin Oncol 29: 111s, 2011Colleoni M, et al. J Clin Oncol 18: 584-590, 2000

Compelling evidence that reduction from standard dose and dose-intensity may compromise OSMany oncologists use ideal body weight to calculate BSA or to CAP BSA at 2.0 m2

Up to 40% of obese patients were undertreated

© 2015 Rising Tide


Dosing of Chemotherapy

Griffs, JJ, et al. J Clin Oncol 30 2012

Pharmacokinetics of some but not all drugs may be altered in obese patients!

© 2015 Rising Tide


Efficacy of Chemotherapy

Litton, J, et al. J Clin Oncol 26 2008

Over 1100 Patients receiving neoadjuvant chemotherapy (1990-2004, using actual weight at MDACC)

Overweight

Obese Patients

40% to achieve pCR (pathological complete remission)

© 2015 Rising Tide


Compliance of Hormonal Therapy

Henry, NL, et al. J Clin Oncol 30 2012

AIs (anastrozole, letrozole and exemestane) have similar benefits and toxicities

Myalgia & Arthralgia in up to 60% patients

Median time to discontinuation is 6 months

Discontinuation Rate 30-50%, 75% due to musculoskeletal toxicities

© 2015 Rising Tide


Risk Factors for AI-induced Arthralgia

Henry, NL, et al. J Clin Oncol 30 2012

Previous HRT or young age

Previous chemotherapy, in particular, Taxane

Obesity

© 2015 Rising Tide


Efficacy of Hormonal TherapyATAC (Arimidex, TAM, Alone or in Combination)

Sestak I et al. JCO 2010;28:3411-3415

Hazard plots for anastrozole versus tamoxifen by body mass index (BMI) group

© 2015 Rising Tide

Obesity: Worse Outcome

ATAC (Arimidex, TAM, Alone or in Combination)

All breast cancer recurrences according to body mass index (BMI) groupSestak I et al. JCO 2010;28:3411-3415

© 2015 Rising Tide

Obesity:

After Diagnosis

Clin Oncol (R Coll Radiol). 2002 Feb;14(1):64-7. Clinical Nutrition 29 (2010) 187–191

~ 60% of patients gained weight after adjuvant or neoadjuvant chemotherapy with average weight gain 6-10 Ibs

The effect of adjuvant hormonal therapy is controversial

~ 50% breast cancer survivors are overweight or obese

© 2015 Rising Tide

Obesity: Worse Prognosis

Marianne Ewertz, Maj-Britt Jensen, KatrínA´ . Gunnarsdo´ttir, Inger Højris, Erik H. Jakobsen

Danish Breast Cancer Cooperative Group

Dataset of 53816 patients

18967 patients (35%): BMI data available

30 years of follow-up: 1977-2006

© 2015 Rising Tide


Marianne Ewertz, Maj-Britt Jensen, KatrínA´ . Gunnarsdo´ttir, Inger Højris, Erik H. JakobsenCumulative incidence of recurrence in relation to body mass index (BMI)

© 2015 Rising Tide


Chan DSM, et al. Annals of Oncology June, 2014

82 Studies: ~ 213, 000 breast cancer survivors with 41,500 deaths (23,200 breast cancer-specific death)

BMI >30, increases total mortality 40% (75% for premenopausal, 35% for postmenopausal)

BMI and Breast Cancer Survival

© 2015 Rising Tide

OBESITY AND BREAST CANCER

1. Obesity is a risk factor for breast cancer

2. Diagnostic and therapeutic challenges

3. Obesity is a poor prognostic factor

© 2015 Rising Tide

© 2015 Rising Tide

10/1/2014

Education and Awareness

Clinical Guidance Research Promotion

Obesity and Breast Cancer: How to Assess Your Patient

Presented By:Amy Malensek RN OCN CBCN

© 2015 Rising Tide

Assessment Barriers

• Barriers to assessing patients with obesity

• How to approach patients with obesity

• Different assessment styles and goals based on the timeline of your patient’s treatment plan

© 2015 Rising Tide

Barriers

• Knowledge base– Being comfortable with knowledge that you have

regarding the disease process and treatment plan

• Personal comfort zone– Being comfortable with asking the right questions

at the right time– Knowing how and when to begin those difficult

conversations

© 2015 Rising Tide

Physical Assessment

• Head to toe: remember side effects of disease, as well as treatment

• Assessment will have a different focus depending on the stage of treatment

• Before Treatment• During Treatment• After Treatment

© 2015 Rising Tide

Mobility

• Are they able to move around with ease?• Are they having difficulty with ADLs• Is it related to Pain or Neuropathy,

Or Both

© 2015 Rising Tide

Appetite

• Decreased or Increased• Have their taste sensations changed• Are they having

Nausea/Diarrhea/Constipation

© 2015 Rising Tide

Psychosocial Assessment

• Understanding that all patients will have psychosocial needs

• Fatigue• Irritability• Anxiety• Depression (more than 47% of breast cancer patients

report suffering from some level of depression)

© 2015 Rising Tide

Other Barriers

• Do they have underlying metabolic disorders– Thyroid– Hormonal imbalances– Other Genetic disorders

© 2015 Rising Tide

Other Barriers

• Are they afraid to talk to you…..

• Are you afraid to talk to them

© 2015 Rising Tide

How Can I Improve

• Understanding your personal barriers will allow you to become more open to your patient’s needs

• Practice your communication and assessment skills

© 2015 Rising Tide

Conclusion

• Gaining a new understanding into the patient perspective will allow for you to better understand the needs of your patient

• Active listening and careful observation will give you a much clearer picture of what your patient is experiencing

• Realizing the stigma that has been placed on patients with obesity can improve the patient experience

© 2015 Rising Tide

Clinical Challenges of Obesity & Breast Cancer

Presented By:Brenda Keith RN MSN AOCNS

Physical Challenges

• Challenges in screening and diagnosis• Surgical complications• Implications for treatment• Survivorship issues

PHYSICIAL: Challenges in Screening and Diagnosis

• Women may delay or avoid screening– Embarrassment– Pain– Inadequate equipment– Negative provider attitudes– Unsolicited weight-loss advice and routine weighing

• Provider barriers– Difficulty doing exams– Inadequate equipment and education– Challenges overcoming patient barriers and refusal

Ferrante, et al. (2010) Family Physicians' Barriers to Cancer Screening in Extremely Obese Patients

Challenges of Imaging Studies

Miller, J. (2005). Imaging and obese patients. From Radiology Rounds: A newsletter for referring physicians, Massachusetts General Hopsital, Department of Radiology. Retrieved March 20, 2015, from http://www.mghradrounds.org/index.php?src=gendocs&link=2005_july

PHYSICAL: Surgical complications

• Complications after breast reconstruction– Wound complications– VTE– Pneumonia– Implant and flap failure

Fischer, J., et al. (2013). Impact of obesity on outcomes in breast reconstruction: Analysis of 15,937 patients from the ACS-NSQIP datasets. Journal of the American College of Surgeons, 217(4), 656-664.

PHYSICAL: Treatment complications

• Radiation–Radiation pneumonitis– Fibrosis–Poorer cosmetic outcome– Ipsilateral arm edema

Iyengar, et al. (2013). Obesity, Inflammation and Cancer. In A. Dannenberg & N. Berger (eds.) Obesity, Inflammation and Cancer. Springer: New York.

Psychosocial Implications

• Bias, stigma and discrimination due to weight– Bias or stigma: negative weight-related attitudes

toward an overweight or obese individual– Discrimination: Unequal, unfair treatment of

people because of their weight• Perception about causes of obesity• Consequences– Personal and social well-being– Emotional health

Puhl, R. Understanding the Stigma of Obesity and its Consequences. Obesity Action Coalition.


• Considerable social consequences associated with obesity

• The language used to discuss obesity can either promote or reduce weight bias and stigmatization

Puhl, R. (2014). Language and Obesity: Putting the person before the disease. Medscape. July 24, 2014.


• Weight bias in health care– Perceptions of obesity among HCPs– Reactions of patients to weight discrimination

Nadglowski, J. (2014). Understanding Obesity: Weight stigma and its consequences. Obesity Action Coalition. http://www.nbch.org/nbch/files/ccLibraryFiles/Filename/000000003266/Nadglowski%20-%20Key%20Note.pdf


• Patients may feel overwhelmed by cancer diagnosis

• Additional burden of talking about their weight

Lawrence, L. (2014). Cancer Care Faces a Growing Crisis: Obesity. ASCO Connection, September 2014, 16-23.


• Role of HCP in addressing weight bias and stigma of obesity

• Addressing weight loss may be a new area of discussion– Discussing obesity may be uncomfortable for

healthcare providers

Lawrence, L. (2014). Cancer Care Faces a Growing Crisis: Obesity. ASCO Connection, September 2014, 16-23.

• Clinicians lack knowledge and critical skills in assessment and management of obesity– Providers often do not counsel patients about

weight– If providers do counsel patients about weight,

they often do not discuss specific recommendations for behavior change

– Reasons for inadequate counseling• Lack of training and competency in obesity

management

Jay, M., et al. 2010; Kraschnewski, M., et al. 2013; Huang, J., et al. 2004; Jay, M., et al. 2008

Addressing Obesity in the Clinic

Society of Gynecologic Oncology

Addressing Obesity in the Clinic

• Ask permission to discuss weight• Acknowledge that obesity is a disease with

multiple causes– Culture– Environment– Genetics

• Understand that patients may feel blame, shame, and guilt about their weight

Vallis, M., et al. 2013; Via, M. & Mechanick, J. 2014; Dalle, G., et al. 2013; Ahmed, S., et al. 2002

Summary

• Ways to reduce weight stigma– Approach patients with sensitivity– Recognize complex etiology of obesity– Avoid stereotyping– Emphasize behavior changes– Offer concrete advice– Acknowledge difficulty of lifestyle changes– Create a supportive healthcare environment

O’Reilly, K. (2013). Confronting bias against obese patients. . From American Medical News. Retrieved Mach 20, 2015 from http://www.amednews.com/article/20130902/profession/130909988/4/

Obesity and Breast Cancer: Supplement Usage and

Contraindications

Presented By:Dr. Adam Kerievsky

© 2015 Rising Tide

Objectives

• Introduction• Regulation of Weight-Loss Dietary

Supplements• Three common ingredients in weight loss

supplements• Safety considerations• Drug-Herb interactions

© 2015 Rising Tide

Introduction

• Americans spend roughly $2 billion a year on weight-loss dietary supplements [2]

• Weight-loss is one of the top 20 reasons why people take dietary supplements.[3]

© 2015 Rising Tide

Dietary supplements promoted for weight loss

• Manufacturers market these products with various claims:–Reduce macronutrient absorption–Reduce appetite–Reduce body fat, and weight –Increase metabolism and

thermogenesis.

© 2015 Rising Tide

Use of nonprescription dietary supplements for weight loss is common among Americans.

J Am Diet Assoc. 2007 Mar;107(3):441-7.[5]

• Adults aged > or =18 years (n=9,403) completed a cross-sectional population-based telephone survey of health behaviors.

© 2015 Rising Tide

Study Details:

• Approximately 15.2% of U.S. adults have used a weight-loss dietary supplement at some point in their lives, with more women reporting use (20.6%) than men (9.7%), highest use was among women aged 18 to 34 years (16.7%)

© 2015 Rising Tide

Dietary supplements for body-weight reduction: a systematic review.

Am J Clin Nutr 2004;79:529-36.

• The objective of the study was to assess the evidence on the effectiveness of dietary supplements in reducing body weight.

• Five systematic reviews and meta-analyses and 25 additional trials were included and reviewed.

© 2015 Rising Tide

Study Details:

• The reviewed studies provide some encouraging data but no evidence beyond a reasonable doubt that any specific dietary supplement is effective for reducing body weight.

© 2015 Rising Tide

Regulation of Weight-Loss Dietary Supplements

• Unlike drugs, dietary supplements do not require premarket review or approval by the FDA.

© 2015 Rising Tide

Tainted products

• FDA has discovered hundreds of "dietary supplements" containing drugs or other chemicals, particularly in products for weight loss.

• The "extra ingredients" generally aren't listed on the label, but could cause serious side effects or interact in dangerous ways with medicines or other supplements.

© 2015 Rising Tide

Tainted Products

• FDA has found weight-loss products tainted with prescription drug ingredients such as:–Sibutramine –Fluoxetine –Triamterene

© 2015 Rising Tide

Common Ingredients in Weight-Loss Dietary Supplements

• Caffeine (as added caffeine or from guarana, kola nut, yerba mate, or other herbs)– Evidence of Safety– Evidence of Efficacy– Proposed Mechanism of Action

© 2015 Rising Tide


• Green coffee bean extract (Coffea aribica, Coffea canephora, Coffea robusta– Evidence of Safety– Evidence of Efficacy– Proposed Mechanism of Action

Marketer Who Promoted a Green Coffee Bean Weight-Loss Supplement Agrees to Settle FTC Charges

• The FTC charged that Duncan and his companies, Pure Health LLC and Genesis Today, Inc., deceptively claimed that the supplement could cause consumers to lose 17 pounds and 16 percent of their body fat in just 12 weeks without diet or exercise, and that the claim was backed up by a clinical study. [10]

© 2015 Rising Tide

Marketer Who Promoted a Green Coffee Bean Weight-Loss Supplement Agrees to Settle FTC Charges

• Lindsey Duncan and the companies he controlled agreed to settle Federal Trade Commission charges that they deceptively touted the supposed weight-loss benefits of green coffee bean extract through a campaign that included appearances on The Dr. Oz Show, The View, and other television programs.

• After appearing on Dr. Oz, Duncan and his companies sold tens of millions of dollars’ worth of the extract, according to the FTC.

• Under the FTC settlement, the defendants are barred from making deceptive claims about the health benefits or efficacy of any dietary supplement or drug product, and will pay $9 million dollars.[10]

© 2015 Rising Tide


• Green tea (Camellia sinensis) and green tea extract– Evidence of Safety– Evidence of Efficacy– Proposed Mechanism of Action

© 2015 Rising Tide

Potential Mechanisms for Interactions with pharmaceuticals

• Combined use of Herbs with Pharmaceuticals may increase or decrease the effects of either substance, leading potentially to greater toxicity or treatment failure.

• Most known drug interactions are due to changes in metabolic routes related to altered expression or functionality of cytochrome P450 (CYP) isoenzymes, responsible for activating or inactivating many drugs.

• CYP3A4/5 is perhaps most important as it is involved in metabolizing almost half of all conventional medications. CYP2D6 and CYP2C9 rank second and third, respectively, in the number of drugs affected.[12]

© 2015 Rising Tide

Variable inhibitory effect of different brands of commercial herbal supplements on human CYP3A4

• Among the supplements tested, Green Tea Extract produced the most pronounced inhibition of CYP3A4, which ranged from 5.6% by Nature's Resource to 89.9% by Natrol Green Tea Extract (GTE) product.

• This study suggests that GTE use may cause significant interactions with drugs metabolized by CYP3A4.

• However, the effect on CYP3A4 varied among different brands of GTE, possibly due to variations in their content of the herbal product's active ingredients. [13]

• Botanicals pose the highest risk for interactions and thus require the most vigilance.

© 2015 Rising Tide

Is the patient currently receiving cytotoxic, targeted, or immunotherapy?

No

Yes

Is the patient currently on hormonal or androgen deprivation therapy?

No

Is the patient currently off chemotherapy or on a drug holiday?

No

Has the patient completed therapy or does not need therapy at this time?

Figure 1. Approach to patients taking a particular herbal product

Yes Yes Yes

High risk for drug-herb interaction. Discuss risk with patient. Where appropriate, suggest non-herbal alternative for side effect mitigation, immune function support, and/or improving quality of life

Similar to Scenario 1. High risk for drug-herb interaction. Discuss risk with patient. Where appropriate, suggest non-herbal options.

If they not taking other medications with a narrow therapeutic index/ high risk for adverse effects (e.g. methadone, warfarin, benzodiazepines), consider allowing them to take herbal products during the drug holiday. Recommend that they discontinue herbal products at least 7 days prior to returning for re-evaluation to allow a sufficient wash out period should they need to resume anti-cancer therapy at their follow up visit. If the patient is on medications that may pose a risk, recommend non-herbal options and discuss the relative risks.

Similar to Scenario 3, as long as the patient is not on other medications that may pose a risk, consider allowing use of herbal products. If the patient has a hormone-sensitive cancer, advise against the use of any herbs with estrogenic potential.

Scenario 1 Scenario 2 Scenario 3 Scenario 4

© 2015 Rising Tide

Websites

• Epocrates.com• Naturaldatabase.com• Pubmed.org-search for the herb AND CYP450• micromedexsolutions.com• Consumerlab.com

© 2015 Rising Tide

Conclusion

Obesity and Breast Cancer: Nutrition

Presented By:Sarah Kiser MS RD

Background• Overweight, poor diet, and physical inactivity:– Increase risk and recurrence – Associated with poorer prognosis

• Many breast cancer survivors are overweight at time of diagnosis and gain weight during treatment

Thomson CA. Nutr Clin Pract. 2012;27:636-650.

• Increased risk for other chronic diseases− Heart disease − Diabetes− High blood pressure

Nutrition Assessment

• Assessment– Weight history– Diet history and food

preferences– Bioelectrical impedance

analysis (BIA)– Energy needs– Waist circumference– Physical activity

Nutrition Assessment

• BMI = body mass index; kg/m2 • BMR = basal metabolic rate; the amount of

energy expended while at rest

Metabolic Health

Padwal RS, Pajewski NM, Allison DB, Sharma AM. CMAJ. 2011;183(14):E1059-E1066.Gunter MJ, Xie X, Xue X, et al. Cancer Res. 2015;75(2):270-274.

• Edmonton Obesity Staging System – independently predicted increased mortality even after adjustment for adiposity

Nutrition Intervention

• Intervention– Education and counseling– Diet modification– Physical activity

Diet Modification• National Weight Control Registry– 78% eat breakfast daily– 75% weigh themselves at least once a week– 62% watch less than 10 hours of TV per week– 90% exercise about 1 hour per day

• Macronutrient composition not as important as negative calorie balance

• Meal replacements may be useful tool• Food and activity tracking

http://nwcr.ws/default.htm

Diet Modification

• Energy needs– Indirect calorimetry• Metabolic cart• Handheld calorimeters

– Estimated BMR equations• Mifflin-St. Jeor formula

– Men: BMR = 10 x weight (kg) + 6.25 x height (cm) – 5 x age (y) + 5

– Women: 10 x weight (kg) + 6.25 x height (cm) – 5 x age (y) – 161

Mifflin MD, St Jeor ST, Hill LA, et al. Am J Clin Nutr. 1990;51(2):241-247.Frankenfield DF, Roth-Yousey L, Compher C, et al. J Acad Nutr Diet. 2005;105(5):775-789.

Diet Modification

• American Institute for Cancer Research (AICR) guidelines– Avoid sugary beverages– Limit consumption of energy-dense foods

(particularly processed foods high in sugar, high in sodium, low in fiber, and high in fat)

– Eat a variety of vegetables, fruits, whole grains, and legumes

http://www.aicr.org

Diet Modification

• AICR guidelines– Limit consumption of red meat to <18 oz/wk and

avoid processed meats– Limit alcoholic drinks to two for men and one for

women daily– Be as lean as possible without becoming underweight– Be physically active for at least 30 minutes every day– Do not rely on supplements to protect against cancer

http://www.aicr.org

Physical Activity

• 2008 Physical Activity Guidelines for Americans– Avoid inactivity– Achieve at least 150 minutes of moderate

intensity PA or 75 minutes of vigorous activity PA per week or a combination• At least 3 days per week• At least 10 minute bouts

– Muscle strengthening 2x/week – at least one set for 8-12 muscle groups

Physical Activity

• PA for weight maintenance– 150-200 minutes per week to prevent a weight

gain of <3% in most adults

• PA for weight loss– <150 minutes/week – minimal weight loss– 150-225 minutes/week – moderate weight loss (2-

3 kg) 30-45 minutes on 5 days per week– 225-420 minutes/week – significant weight loss

(5-7.5 kg) 30-60 minutes per day

American College of Sports Medicine. Medicine and Science in Sport and Exercise. 2009;41(2):459-471.

Dietary factors

– ↑ risk• Alcohol – even low to moderate intake

– Women’s Health Initiative (WHI)» 1 alcoholic drink daily associated with 82% greater risk for

breast cancer» Follow-up analysis – ER+ disease associated with alcohol

intake– LACE cohort

» Alcohol intake at >3 drinks/week increased recurrence risk by 35%, particularly in postmenopausal and overweight/obese women

– Recommendation: <1 drink/day

Thomson CA. Nutr Clin Pract. 2012;27:636-650.Li CI, Chlebowski RT, Freiberg M, et al. J Natl Cancer Inst. 2010;102(18):1422-1431.

Dietary Factors

– ↑ risk• Dietary fat

– Women’s Intervention Nutrition Study (WINS)» Low-fat diet group: 24% lower risk of relapse than control

group after 5 years of follow-up » Had only modest weight loss – 2.7 kg less than control

group at 5 years– Another epidemiological analysis showed that higher intake of

butter, margarine, and lard was associated with 30% higher risk for recurrent disease

Thomson CA. Nutr Clin Pract. 2012;27:636-650.Li CI, Chlebowski RT, Freiberg M, et al. J Natl Cancer Inst. 2010;102(18):1422-1431.Chlebowski RT, Blackburn GL, Thomson CA, et al. J Natl Cancer Inst. 2006;98(24):1768-76.Blackburn GL, Wang KA. Am J Clin Nutr. 2007;86(suppl):878S-81S.

Dietary Factors

– ↓ risk• Vegetables and fruits

– Dietary fiber can modify estrogen concentration– Women’s Healthy Eating and Living (WHEL) study

» Women who ate at least 5 servings of fruits and vegetables per day, along with exercise equivalent to walking 30 minutes 6 days/week had 50% reduced risk of recurrence regardless of weight loss

Thomson CA. Nutr Clin Pract. 2012;27:636-650.Li CI, Chlebowski RT, Freiberg M, et al. J Natl Cancer Inst. 2010;102(18):1422-1431.Pierce JP, Stefanick ML, Flatt SW, et al. JCO. 2007;25(17): 2345-2351.

Summary

• Lifestyle modification even with modest weight loss can attenuate risk

• Overall diet quality matters• Be available as support system and encourage

small changes

Documents

Obesity and Breast Cancer: An Ever Growing Problem Presented By: Dr. Jaixin Niu Dr. Adam Kerievsky Brenda Keith RN MSN OCN Amy Malensek RN OCN CBCN Sara